Dr. Jonathon B. Cohen, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Florida College of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 204
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: University of Florida College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
GA license 069784 · GA license 69784 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Emory University Hospital Atlanta, GA
- Emory University Hospital Midtown Atlanta, GA
- Saint Joseph's Hospital of Atlanta, Inc Atlanta, GA
- Emory Johns Creek Hospital Johns Creek, GA
Medical groups
- The Emory Clinic Inc (3,568 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 204
- Services billed
- 556
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 187 | 144 |
| Established patient office or other outpatient visit, 30-39 minutes | 116 | 71 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
| Established patient office or other outpatient visit, 40-54 minutes | 14 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brukinsa (zanubrutinib) | 169 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Atlanta, GA | 115 |
| Venclexta (venetoclax) | 82 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Atlanta, GA | 31 |
| Acyclovir Other prescribers in Atlanta, GA | 27 |
| Entecavir | 25 |
| Imbruvica (ibrutinib) | 24 |
| Calquence (acalabrutinib maleate) | 23 |
| Eliquis (apixaban) Other prescribers in Atlanta, GA | 18 |
| Allopurinol Other prescribers in Atlanta, GA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 14 payments worth $12,462 in total to this clinician.
| National Marrow Donor Program | $6,300 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $4,290 |
| Incyte Corporation | $1,713 |
| Janssen Biotech, Inc. | $112 |
| Genmab U.S., Inc. | $25.00 |
| Beone Medicines USA, Inc. | $22.45 |
| Consulting Fee | $12,253 |
|---|---|
| Food and Beverage | $185 |
| Education | $25.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 14, 2025 | Consulting Fee CALQUENCE · Oncology | $2,870 |
| AstraZeneca Pharmaceuticals LP Nov 14, 2025 | Consulting Fee CALQUENCE · Oncology Company’s descriptionResearch Related Service | $1,370 |
| National Marrow Donor Program Jan 10, 2025 | Consulting Fee | $1,350 |
| National Marrow Donor Program Apr 4, 2025 | Consulting Fee | $1,350 |
| National Marrow Donor Program Sep 26, 2025 | Consulting Fee | $1,350 |
| National Marrow Donor Program Dec 30, 2025 | Consulting Fee | $1,350 |
| National Marrow Donor Program Jul 2, 2025 | Consulting Fee | $900 |
| Incyte Corporation Jul 31, 2025 | Consulting Fee Monjuvi · Oncology | $685 |
| Incyte Corporation Oct 9, 2025 | Consulting Fee Monjuvi · Oncology | $685 |
| Incyte Corporation Nov 20, 2025 | Consulting Fee Monjuvi · Oncology | $343 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| National Marrow Donor Program Dec 30, 2025 | Consulting Fee | $1,350 |
| AstraZeneca Pharmaceuticals LP Dec 14, 2025 | Consulting Fee CALQUENCE · Oncology | $2,870 |
| Incyte Corporation Nov 20, 2025 | Consulting Fee Monjuvi · Oncology | $343 |
| AstraZeneca Pharmaceuticals LP Nov 14, 2025 | Consulting Fee CALQUENCE · Oncology Company’s descriptionResearch Related Service | $1,370 |
| Incyte Corporation Oct 9, 2025 | Consulting Fee Monjuvi · Oncology | $685 |
| National Marrow Donor Program Sep 26, 2025 | Consulting Fee | $1,350 |
| Incyte Corporation Jul 31, 2025 | Consulting Fee Monjuvi · Oncology | $685 |
| National Marrow Donor Program Jul 2, 2025 | Consulting Fee | $900 |
| National Marrow Donor Program Apr 4, 2025 | Consulting Fee | $1,350 |
| National Marrow Donor Program Jan 10, 2025 | Consulting Fee | $1,350 |
| Genmab U.S., Inc. Jan 8, 2025 | Education Epkinly · Oncology · in-kind | $25.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 10 companies. The companies reported $1,146,940 in research payments for these studies, mostly to the institutions running them.
- A Multicenter, Open-Label Phase 2 Trial of Acalabrutinib plus Obinutuzumab in Patients with Untreated, Low Tumor Burden Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
AstraZeneca Pharmaceuticals LP - A study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with other anti-cancer agents in participants with relapsed or refractory b-cell non-hodgkin lymphoma (LOTIS-7)
Adc Therapeutics America, Inc. - A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company · Completed · NCT03740529 - Long Term Follow Up of Patients Exposed to Lentiviral Based CD19 Directed CAR T Cell Therapy
Novartis Pharmaceuticals Corporation - A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Eli Lilly and Company · Recruiting · NCT06876662 - A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
Beone Medicines Ltd. · Completed · NCT03332017 - A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies
AstraZeneca UK Limited - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT05409066 - Evaluating the combination of obinutuzumab bendamustine and venetoclax in untreated mantle cell ly
Genentech, Inc. - Ph III GDC 199 GA101 vs GChl in CLL with comorbidities
F. Hoffmann-la Roche AG
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.